ÄϹ¬¼¯ÍÅ

ʧÃß½¹ÂÇÒÖÓôÄÚÉøÍ¸ÔÓÂÒ£¿£¿£¿100Íòйڻ¼ÕßÊý¾Ý£ºÅ®ÐÔ»¼¡°³¤Ð¹ڡ±µÄΣº¦ÊÇÄÐÐÔ2±¶£¡

ͼƬ

¿ËÈÕ £¬£¬£¬£¬£¬¿ÆÑ§¼ÒÃÇÐû²¼ÁË100¶àÍòйڻ¼ÕßµÄÊý¾Ý£ºÆÊÎöÁË22¸ö¹ú¼ÒÖеÄ54ÏîÑо¿¡£¡£¡£¸ÃÑо¿Í³¼ÆÁËÓм¸¶àйڻ¼Õß·ºÆðÁËһϵÁÐеij¤Ð¹ÚÖ¢×´ £¬£¬£¬£¬£¬²¢È·¶¨ÁË»¼ÕâÖÖ¼²²¡µÄΣº¦ÔõÑù»ùÓÚËûÃǵÄÄêËê¡¢ÐԱ𠣬£¬£¬£¬£¬ÒÔ¼°ÊÇ·ñÒòйڶø×¡Ôº¡£¡£¡£

ͼƬ1.png


ÄÐÐÔ¸ü¿ÉÄÜѬȾйںÍËÀÓÚйÚ

Å®ÐÔ»¼¡°³¤Ð¹ڡ±¸ÅÂʸü´ó







Ñо¿·¢Ã÷ £¬£¬£¬£¬£¬³¤Ð¹ڻ¼ÕßÖÐ £¬£¬£¬£¬£¬ÓиߴᆰÈ˵Ä90%×î³õÖ»»¼ÉÏÁËÉÔ΢µÄйڡ£¡£¡£È»¶ø £¬£¬£¬£¬£¬ÔÚ·ºÆð³¤ÐÂ¹Úºó £¬£¬£¬£¬£¬»¼Õߵĵ䷶֢״»á°üÀ¨Æ£ÀÍ¡¢ºôÎü¼±´ÙºÍÈÏÖªÎÊÌ⣨ÈçÄÔÎí£©»òÕâЩӰÏìÒ»Ñùƽ³£¹¦Ð§Ö¢×´µÄ×éºÏ¡£¡£¡£ÕâЩ֢״¶Ô¿µ½¡µÄÓ°ÏìÓë´´ÉËÐÔÄÔËðÉ˵ĺã¾ÃÓ°ÏìÒ»ÑùÑÏÖØ¡£¡£¡£Ñо¿»¹·¢Ã÷ £¬£¬£¬£¬£¬Å®ÐÔ»¼¡°³¤Ð¹ڡ±µÄΣº¦ÊÇÄÐÐÔµÄÁ½±¶¡¢¶ùͯµÄËı¶¡£¡£¡£

ͼƬ2.png

ÃÀ¹ú»ùÒò¹«Ë¾Í¨¹ýÊÓ²ì10ÍòÃûйڻ¼Õß £¬£¬£¬£¬£¬·¢Ã÷ÆäÖÐ7000ÈË·ºÆðºôÎü²»³©¡¢Æ£ÀͺÍÄÔÎíµÈ³¤Ð¹ÚÖ¢×´ £¬£¬£¬£¬£¬Ò»Á¬Ê±¼äÁè¼Ý12ÖÜ¡£¡£¡£ËäÈ»ÄÐÐÔ¸ü¿ÉÄÜѬȾºÍËÀÓÚÐÂ¹Ú £¬£¬£¬£¬£¬µ«Å®ÐÔ»¼ÉÏ¡°³¤Ð¹ڡ±µÄ¸ÅÂʸü´ó¡£¡£¡£
Å®ÐÔÕý³£ÇéÐÎÏÂÓÐÁ½¸öXȾɫÌ帱±¾ £¬£¬£¬£¬£¬ÆäÖаüÀ¨×î¶àµÄÃâÒßÏà¹Ø»ùÒò £¬£¬£¬£¬£¬ÕâÒâζ×Ųî±ðµÄÃâÒß·´Ó¦ÔÚÅ®ÐÔÉíÉϸüΪÏÔ×Å £¬£¬£¬£¬£¬ÈçÀÇ´¯»ò¶à·¢ÐÔÓ²»¯Ö¢µÈ×ÔÉíÃâÒß¼²²¡ £¬£¬£¬£¬£¬Å®ÐÔ»¼Õ߾ͱÈÄÐÐÔ¶à¡£¡£¡£Ô¼Èý·ÖÖ®Ò»¡°³¤Ð¹ڡ±»¼ÕßÓÐ×ÔÉíÃâÒß¼²²¡Ê· £¬£¬£¬£¬£¬ÓâÒ»°ëÓÐÒÖÓô¡¢½¹ÂÇ¡¢ÌÇÄò²¡»òÐÄÔಡµÈ²¡Ê·¡£¡£¡£Ö¢×´ÑÏÖØµ½ÐèҪסԺµÄ»¼Õß·ºÆð³¤Ð¹ڵĸÅÂÊ±ÈÆäËûÈ˸ß10±¶¡£¡£¡£
³¤Ð¹ÚÊÇÒ»ÖÖÖØ´ó¶ø¶¯Ì¬µÄÀú³Ì¡ª¡ªÒ»Ð©Ö¢×´ÏûÊÅ £¬£¬£¬£¬£¬È»ºó¸´·¢ £¬£¬£¬£¬£¬È»ºó·ºÆðеÄÖ¢×´¡£¡£¡£µ«Ñо¿Ö°Ô±»¹²»ÖªµÀÆäÖеÄÔµ¹ÊÔ­ÓÉ¡£¡£¡£


ËäÈ»Ñо¿ÖصãÊÇÓ볤йÚÏà¹ØµÄÈýÖÖ×î³£¼ûµÄÓ°ÏìÒ»Ñùƽ³£¹¦Ð§µÄÖ¢×´ £¬£¬£¬£¬£¬µ«Ò²¿ÉÄܰüÀ¨Ðá¾õºÍζ¾õËðʧ¡¢Ê§Ãß¡¢Î¸³¦µÀÎÊÌâºÍÍ·Í´µÈÖ¢×´¡£¡£¡£µ«ÔÚ´ó´ó¶¼ÇéÐÎÏ £¬£¬£¬£¬£¬ÕâÐ©ÌØÁíÍâÖ¢×´ÓëÖ÷ÒªÖ¢×´Ò»Æð·ºÆð¡£¡£¡£

½Ò¿ªÐ¹ڵIJ¡Àíѧ»úÖÆ

ËÞÖ÷ÃâÒßµ÷ÀíÄÜÁ¦Êǽ¹µã







²î±ðÓÚ¾­µäµÄÃâÒßÑ×Ö¢·´Ó¦ £¬£¬£¬£¬£¬ÔÚйڲ¡¶¾µÄÇÖÂÔÏ £¬£¬£¬£¬£¬³¤Ð¹ڻ¼ÕßµÄÌåÄÚ·ºÆðÁËÁíÒ»ÖÖ¿¹Ñ×ģʽ £¬£¬£¬£¬£¬¼´½»Ì漫»¯¾ÞÊÉϸ°ûµÄÖ÷µ¼¼²²¡Ä£Ê½ £¬£¬£¬£¬£¬Ö±½ÓÓÕ·¢Á˺ã¾ÃÆ£ÀÍ×ÛºÏÕ÷µÄ±¬·¢¡£¡£¡£¸ÃÑо¿ÓÚ2022Äê12ÔÂ2ÈÕ½ÒÏþÔÚCell×Ó¿¯iScienceÉÏ¡£¡£¡£ 

ͼƬ3.png

Ñо¿ÕßÌåÏÖ £¬£¬£¬£¬£¬Ïàʶ³¤Ð¹ڵIJ¡Àíѧ»úÖÆÖ»ÊǵÚÒ»²½°ÕÁË £¬£¬£¬£¬£¬ÏÂÒ»²½Ï£Íû¿ÉÒÔΪÕâЩ¡°À§ÓÚ¡±³¤Ð¹ڵϼÕßÌṩ¸ü¶à¸ÄÉÆºÍÖÎÁƵÄÊֶΣ¡
¼ä³äÖʸÉϸ°û£¨MSC £¬£¬£¬£¬£¬mesenchymal stem cells£©ÊǸÉϸ°û¼Ò×åµÄÖ÷Òª³ÉÔ± £¬£¬£¬£¬£¬Æä¶ÔÃâÒßϵͳµÄµ÷ÀíÌØÕ÷¾ßÓÐË«ÏòÐÔ £¬£¬£¬£¬£¬ÔÚÃâÒßÁ¦µÍÏÂʱ¼ä £¬£¬£¬£¬£¬Æðµ½ÔöÇ¿ÃâÒßµÄ×÷Óà £»£»£»£»¶ø¶Ô¹ýÇ¿µÄÃâÒß·´Ó¦ £¬£¬£¬£¬£¬»á±¬·¢ÒÖÖÆ×÷Óᣡ£¡£
¼ä³äÖʸÉϸ°û£¨MSC£©ÒÀ¸½ÆäÇ¿µÄÃâÒßµ÷ÀíÌØÕ÷ £¬£¬£¬£¬£¬ÔÚÕâ´ÎÒßÇéµÄÖÎÁÆÖÐҲʩչÁËÖ÷Òª×÷Óà £¬£¬£¬£¬£¬¹ØÓÚ·ÀÖÎйڼ°ºóÒÅÖ¢ÓÐÆð¾¢µÄЧӦ¡£¡£¡£

ͼƬ4.png


ÃæÁÙí§ÒâºáÐеÄйڲ¡¶¾ £¬£¬£¬£¬£¬¶à´Î±»¹úÎñÔºµÈ¹ú¼Ò¼¶¾Û»áÌá¼°µÄ»Ö¸´ÆÚѪ½¬ÁÆ·¨ £¬£¬£¬£¬£¬³ÉΪÕü¾ÈÎ£ÖØÖ¢»¼ÕßÉúÃüµÄ¡°ÌØÐ§Ò©¡± £¬£¬£¬£¬£¬»Ö¸´ÆÚѪ½¬ÁÆ·¨ £¬£¬£¬£¬£¬½¹µã¾ÍÊÇʹÓÃÆäÖк¬ÓеÄÓ°ÏóµÄ¿¹Ìå»òϸ°û £¬£¬£¬£¬£¬À´¶Ô¿¹²¡¶¾ £¬£¬£¬£¬£¬ÒÖÖÆÑ¬È¾ £¬£¬£¬£¬£¬µÖ´ï¿µ¸´¡£¡£¡£
еķ¢Ã÷ £¬£¬£¬£¬£¬Ò²Ö¤ÊµÁËTϸ°ûºÍNKϸ°û¶Ô¿¹²¡¶¾µÄǿʢ·´Ó¦ £¬£¬£¬£¬£¬Ô¤Ê¾×źã¾Ã± £»£»£»£»¤ÐÔÃâÒßµÄÉú³¤ £¬£¬£¬£¬£¬Ã÷È·ÁËËÞÖ÷ÃâÒß·´Ó¦ÔÚ²¡¶¾É¨³ýÖÐÊÇÒªº¦×÷Óᣡ£¡£
Å®ÐÔÏà½ÏÓÚÄÐÐÔÀ´Ëµ £¬£¬£¬£¬£¬¸üÒª± £»£»£»£»¤ºÃ×Ô¼º £¬£¬£¬£¬£¬´Ó¸Éϸ°ûºÍÃâÒßϸ°û˫Ч²ãÃæ¾ÙÐлù´¡ÐÞ¸´ £¬£¬£¬£¬£¬´Ó¶øµ÷ÀíÉíÌåÐÔÄÜ £¬£¬£¬£¬£¬Ìá¸ßг´úл £¬£¬£¬£¬£¬ÔöÇ¿ÃâÒßÁ¦ £¬£¬£¬£¬£¬Ê¹ÉíÌåÔ½·¢ÄêÇá £¬£¬£¬£¬£¬Ô½·¢¿µ½¡ÓлîÁ¦¡£¡£¡£
²Î¿¼×ÊÁÏ£º

1¡¢90% of people with long COVID initially had mild symptoms, according to study of 1.2 million people in over 20 countries

2¡¢A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome


ÄϹ¬¼¯ÍÅÍÆ³öÁËһϵÁиÉϸ°ûºÍÃâÒßϸ°ûÊÖÒÕ×Éѯ¼Æ»® £¬£¬£¬£¬£¬ÓÉר¼ÒÍŶӾÙÐж¨ÖÆ¡£¡£¡£

  Ç볤°´Í¼Æ¬Ìí¼Ó¡¾ÄϹ¬¼¯ÍÅר¼Ò×ÉѯºÅ¡¿
    ¾ÙÐÐÒ»¶ÔÒ»×Éѯ
ͼƬ






ÄϹ¬¼¯ÍÅ £¬£¬£¬£¬£¬ÊÇÒ»¼Ò¸ßÐÂÊÖÒÕÆóÒµ £¬£¬£¬£¬£¬×¨×¢ÓÚϸ°ûÊÖÒÕÑо¿Óëת»¯ £¬£¬£¬£¬£¬¿ªÆô¶àÏîÖ×ÁöÃâÒßÖÎÁƵÄÊÖÒÕ¹ÜÏߺÍÒ©Îï¹ÜÏß £¬£¬£¬£¬£¬×ÔÖ÷Ñз¢¡¢×ÔÖ÷Á¢Òì £¬£¬£¬£¬£¬ÓµÓжàÏî֪ʶ²úȨ¡£¡£¡£ÄϹ¬¼¯ÍÅÖÂÁ¦ÓÚÆÕ¼°ÆÕ»Ýϸ°ûÖÎÁÆÊÖÒÕ £¬£¬£¬£¬£¬Ô츣ÓÚ¿í´óÃñÖÚ £¬£¬£¬£¬£¬³Ð¼Ì×Å¡°ÈÃÖ×Áö¿É·À¿ÉÖÎ £¬£¬£¬£¬£¬Ôö½øÈËÀàÅäºÏ¿µ½¡¡±µÄʹÃü £¬£¬£¬£¬£¬ÊØÕýÁ¢Òì¡¢ÐÐÉÆ»ÝÖÚ¡£¡£¡£










¡¾ÍøÕ¾µØÍ¼¡¿